GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Net Cash per Share

Biovica International AB (OSTO:BIOVIC B) Net Cash per Share : kr0.99 (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Biovica International AB's Net Cash per Share for the quarter that ended in Jan. 2024 was kr0.99.

The historical rank and industry rank for Biovica International AB's Net Cash per Share or its related term are showing as below:

OSTO:BIOVIC B' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.61   Med: 7.38   Max: 27.94
Current: 1.75

During the past 9 years, the highest Price-to-Net-Cash Ratio of Biovica International AB was 27.94. The lowest was 1.61. And the median was 7.38.

OSTO:BIOVIC B's Price-to-Net-Cash is ranked better than
76.56% of 849 companies
in the Biotechnology industry
Industry Median: 4 vs OSTO:BIOVIC B: 1.75

Biovica International AB Net Cash per Share Historical Data

The historical data trend for Biovica International AB's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB Net Cash per Share Chart

Biovica International AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only 0.45 1.21 4.74 2.16 1.76

Biovica International AB Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 1.76 1.04 0.52 0.99

Competitive Comparison of Biovica International AB's Net Cash per Share

For the Biotechnology subindustry, Biovica International AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biovica International AB's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biovica International AB's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Biovica International AB's Price-to-Net-Cash falls into.



Biovica International AB Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Biovica International AB's Net Cash per Share for the fiscal year that ended in Apr. 2023 is calculated as

Net Cash per Share (A: Apr. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(114.327-33.652-0)/45.7414
=1.76

Biovica International AB's Net Cash per Share for the quarter that ended in Jan. 2024 is calculated as

Net Cash per Share (Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(105.238-22.29-0)/84.0556
=0.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB  (OSTO:BIOVIC B) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Biovica International AB Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biovica International AB (OSTO:BIOVIC B) Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB (OSTO:BIOVIC B) Headlines

No Headlines